Research programme: antisense drug therapies - GlaxoSmithKline/Ionis Pharmaceuticals

Drug Profile

Research programme: antisense drug therapies - GlaxoSmithKline/Ionis Pharmaceuticals

Alternative Names: ISIS-AATRx; ISIS-GSK5Rx; ISIS-RHO-2.5Rx

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Isis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Alpha 1 adrenergic receptor modulators; Alpha 1 antitrypsin modulators; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Retinitis pigmentosa
  • No development reported Alpha 1-antitrypsin deficiency; Blindness; Eye-Disorders; Infections

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for preclinical development in Eye-disorders in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Blindness in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top